Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.36 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8967965 | 0.80 | LMNA (0.50) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11501996 | 0.77 | LMNA (0.47) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL8968603 | 0.74 | LMNA (0.53) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL11870178 | 0.74 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Zinc Ion SCHEMBL14920928 | 0.74 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL4727419 | 0.74 | LMNA (0.44) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Potassium Ion SCHEMBL11501588 | 0.73 | LMNA (0.42) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL6813499 | 0.73 | LMNA (0.42) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| Mannitol SCHEMBL27645017 | 0.71 | LMNA (0.73) | LMNAL3MBTL1PDE4ATDP1USP2 | |
| SCHEMBL2520025 | 0.70 | LMNA (0.40) | LMNAL3MBTL1PDE4ATDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-110256336-A | Nitogen-contained heterocycle derivant with 2- imino group and the pest control agent comprising it | 明治制果药业株式会社 | 2019-09-20 | — | — | CN | disclosed |
| CN-109705032-A | Nitogen-contained heterocycle derivant with 2- imino group and the pest control agent comprising it | 明治制果药业株式会社 | 2019-05-03 | — | — | CN | disclosed |
| CN-108495862-A | Topical formulations | 亚尼塔公司 | 2018-09-04 | — | — | CN | disclosed |
| CN-107445940-A | Quinzolone derivatives as 5 substitutions of antitumor agent | 细胞基因公司 | 2017-12-08 | — | — | CN | disclosed |
| CN-106083812-A | The solid form of 3 (5 amino 2 methyl 4 oxygen 4H quinazoline 3 base) piperidines 2,6 diketone and pharmaceutical composition thereof and purposes | 细胞基因公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105899196-A | Formulations of (S) -3- (4- ((4- (morpholinylmethyl) benzyloxy) -1-oxoisoindolin-2-yl) piperidine-2, 6-dione | 细胞基因公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-103562197-B | Solid forms of 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2, 6-dione, and pharmaceutical compositions and uses thereof | CELGENE CORP. (US) | 2016-05-11 | — | — | CN | disclosed |
| CN-105142615-A | The formulation cell company established the state of cyclopropanecarboxylic acid {2- [ (1S) -1- (3-ethoxy-4-methoxy-phenyl) -2-methanesulfonyl-ethyl ] -3-oxo-2, 3-dihydro-1H-isoindol-4-yl } -amide: state of telahua | CELGENE CORP | 2015-12-09 | — | — | CN | disclosed |
| CN-105017212-A | 5-substituted quinazolinone derivatives using as antineoplastic agent | CELGENE CORP | 2015-11-04 | — | — | CN | disclosed |
| CN-102281897-A | Vaccination of poxvirus vectors by mechanical disruption of the epidermis | — | 2011-12-14 | — | — | CN | disclosed |
| CN-102112463-A | 5-substituted isoindoline compounds | CELGENE CORP | 2011-06-29 | — | — | CN | disclosed |
| CN-101679380-A | 4' -O-substituted isoindoline derivatives and compositions comprising and methods of use | CELGENE CORP | 2010-03-24 | — | — | CN | disclosed |
| CN-101578277-A | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2009-11-11 | — | — | CN | disclosed |
| CN-101535291-A | 5-substituted quinazolinone derivatives as antitumor agents | CELGENE CORP (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-101340931-A | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | COLEY PHARM GMBH (DE) | 2009-01-07 | — | — | CN | disclosed |
| CN-101005828-A | Compositions comprising a mucoadhesive protein and an activeprinciple for mucosal delivery of said agents | VIRUN INC (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1678188-A | Nucleic acid compositions for modulating immune responses | COLEY PHARM GROUP INC (US) | 2005-10-05 | — | — | CN | disclosed |
| WO-2004019956-A1 | ORGANOPHOSPHOROUS COMPOUNDS FOR THE TREATMENT OF HELMINTHIC INFECTIONS | BIOAGENCY AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| US-5232441-A | Method of treating schistosomal infestations by iontophoresis | PHYSION S.R.L. (IT) | 1993-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | PTPN11, PTPN1, PTPN7 | PDE4A 724/4885CA4 2439/4885LMNA 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.